172 results
Page 2 of 9
425
nz9vehl
30 May 23
Business combination disclosure
4:21pm
8-K
1ncy7
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
xo85q
22 May 23
Business combination disclosure
7:01am
8-K
ukq3ln8z50fjtu
22 May 23
Other Events
6:59am
8-K
EX-99.1
k4ikc4
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
utptpl15y ryam
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
6wf7wxj540j9nd1o0
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-99.1
l54squyavs4
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-10.1
7ddyg dnxhhil79r
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
ybx8s718gj490e0ys9
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
59tliocy5xqod78k 8n
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
7z7l8ii ck7ns
8 Nov 22
Regulation FD Disclosure
7:40am
8-K
EX-99.1
upqlohlr1gzb1p
25 Oct 22
Adaptimmune Enhances its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
8:10am
8-K
EX-99.1
fytbd0ojzpagofivbbe
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
1hdxawiuf15c18w3k
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am